|
1
|
Myers JN, Elkins T, Roberts D and Byers
RM: Squamous cell carcinoma of the tongue in young adults:
Increasing incidence and factors that predict treatment outcomes.
Otolaryngol Head Neck Surg. 122:44–51. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hernández-Guerrero JC, Jacinto-Alemán LF,
Jiménez-Farfán MD, Macario-Hernández A, Hernández-Flores F and
Alcántara-Vázquez A: Prevalence trends of oral squamous cell
carcinoma. Mexico City’s General Hospital experience. Med Oral
Patol Oral Cir Bucal. 18:e306–e311. 2013.PubMed/NCBI
|
|
3
|
Bagan J, Sarrion G and Jimenez Y: Oral
cancer: clinical features. Oral Oncol. 46:414–417. 2010. View Article : Google Scholar
|
|
4
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duffy MJ, Mullooly M, O’Donovan N, Sukor
S, Crown J, Pierce A and McGowan PM: The ADAMs family of proteases:
new biomarkers and therapeutic targets for cancer? Clin Proteomics.
8:92011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin J, Luo J and Redies C: Differential
expression of five members of the ADAM family in the developing
chicken brain. Neuroscience. 157:360–375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murphy G: The ADAMs: signalling scissors
in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins - therapeutic potential in cancer. Curr Cancer Drug
Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan S, Lei S and Wu S: ADAM10 is
overexpressed in human hepatocellular carcinoma and contributes to
the proliferation, invasion and migration of HepG2 cells. Oncol
Rep. 30:1715–1722. 2013.PubMed/NCBI
|
|
10
|
Doberstein K, Pfeilschifter J and Gutwein
P: The transcription factor PAX2 regulates ADAM10 expression in
renal cell carcinoma. Carcinogenesis. 32:1713–1723. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gaida MM, Haag N, Günther F, et al:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
12
|
Guo J, He L, Yuan P, et al: ADAM10
overexpression in human non-small cell lung cancer correlates with
cell migration and invasion through the activation of the Notch1
signaling pathway. Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
|
|
13
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prox J, Willenbrock M, Weber S, et al:
Tetraspanin15 regulates cellular trafficking and activity of the
ectodomain sheddase ADAM10. Cell Mol Life Sci. 69:2919–2932. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Turner SL, Blair-Zajdel ME and Bunning RA:
ADAMs and ADAMTSs in cancer. Br J Biomed Sci. 66:117–128.
2009.PubMed/NCBI
|
|
16
|
Jones AV, Lambert DW, Speight PM and
Whawell SA: ADAM 10 is over expressed in oral squamous cell
carcinoma and contributes to invasive behaviour through a
functional association with αvβ6 integrin. FEBS Lett.
587:3529–3534. 2013.PubMed/NCBI
|
|
17
|
Shao Y, Zhang SQ, Quan F, Zhang PF and Wu
SL: MicroRNA-145 inhibits the proliferation, migration and invasion
of the human TCA8113 oral cancer line. Oncol Lett. 6:1636–1640.
2013.PubMed/NCBI
|
|
18
|
Lee SB, Schramme A, Doberstein K, et al:
ADAM10 is upregulated in melanoma metastasis compared with primary
melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Y, Chen W, Zhang Y, Hamburger AW, Pan H
and Zhang Z: Suppression of salivary adenoid cystic carcinoma
growth and metastasis by ErbB3 binding protein Ebp1 gene transfer.
Int J Cancer. 120:1909–1913. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Armanious H, Gelebart P, Anand M, Belch A
and Lai R: Constitutive activation of metalloproteinase ADAM10 in
mantle cell lymphoma promotes cell growth and activates the
TNFα/NFκB pathway. Blood. 117:6237–6246. 2011.PubMed/NCBI
|
|
21
|
Zheng X, Jiang F, Katakowski M, Lu Y and
Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol
Carcinog. 51:150–164. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ebsen H, Schröder A, Kabelitz D and
Janssen O: Differential surface expression of ADAM10 and ADAM17 on
human T lymphocytes and tumor cells. PLoS One. 8:e768532013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Normanno N, De Luca A, Bianco C, et al:
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene.
366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan Y, Shirakabe K and Werb Z: The
metalloprotease Kuzbanian (ADAM10) mediates the transactivation of
EGF receptor by G protein-coupled receptors. J Cell Biol.
158:221–226. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Millichip MI, Dallas DJ, Wu E, Dale S and
McKie N: The metallo-disintegrin ADAM10 (MADM) from bovine kidney
has type IV collagenase activity in vitro. Biochem Biophys Res
Commun. 245:594–598. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan Y, Han C, Wang C, et al: ADAM10
promotes pituitary adenoma cell migration by regulating cleavage of
CD44 and L1. J Mol Endocrinol. 49:21–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Solanas G, Cortina C, Sevillano M and
Batlle E: Cleavage of E-cadherin by ADAM10 mediates epithelial cell
sorting downstream of EphB signalling. Nat Cell Biol. 13:1100–1107.
2011. View
Article : Google Scholar : PubMed/NCBI
|
